IDEXX Reports Q1 Revenue of $1.14B, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy IDXX?
Reports Q1 revenue $1.14B, consensus $1.11B. "Excellent commercial execution delivered exceptional first quarter results and positions IDEXX for continued strength through 2026," said Jay Mazelsky, President and Chief Executive Officer. "IDEXX Cancer Dx platform momentum continues to build with the recent International launch and growing adoption in the U.S., and our IDEXX inVue Dx roll-out further advances our innovation-driven growth strategy. Initial customer response to the controlled launch of IDEXX inVue Dx FNA has been very encouraging and supports broadening access over the remainder of the year. As I transition from the CEO role, IDEXX remains well-positioned for continued success, and I look forward to continuing to work with Mike Erickson to drive long-term sustained growth in the business."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDXX
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 560.110
Low
750.00
Averages
792.78
High
850.00
Current: 560.110
Low
750.00
Averages
792.78
High
850.00
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEXX Laboratories Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: IDEXX reported a 14% year-over-year revenue increase and an 11% organic growth in Q1 2026, with earnings per share at $3.47, reflecting the company's strong performance driven by innovation and a global customer base.
- Strong Instrument Sales: CAG instrument revenues saw a 28% organic growth, primarily due to the strong sales of 1,100 IDEXX inVue Dx analyzers, indicating the company's increasing competitiveness in the high-end diagnostic equipment market.
- International Market Expansion: The successful launch of Cancer Dx for canine lymphoma in Europe and Australia, with nearly 70% of tests run as part of a panel in North America, marks IDEXX's further penetration into global markets.
- Optimistic Future Outlook: IDEXX raised its full-year revenue guidance for 2026 to between $4.675 billion and $4.760 billion, with expected earnings per share between $14.45 and $14.90, demonstrating management's confidence in future performance.
See More
IDEXX Laboratories Q1 Earnings Beat Expectations
- Earnings Beat: IDEXX reported Q1 GAAP EPS of $3.47, exceeding expectations by $0.06, indicating sustained profitability and competitive strength in the market.
- Significant Revenue Growth: The company achieved revenue of $1.14 billion, a 14.2% year-over-year increase, surpassing market expectations by $30 million, demonstrating strong product demand, particularly in the CAG Diagnostics segment.
- 2026 Revenue Guidance Raised: IDEXX increased its 2026 revenue guidance to $4.675 billion to $4.76 billion, exceeding market consensus by $420 million, with expectations that CAG Diagnostics will drive continued growth, boosting investor confidence.
- EPS Outlook Upgraded: The company raised its 2026 EPS outlook to $14.45 to $14.90, reflecting a $0.13 increase from prior guidance midpoint, supported by optimistic expectations for revenue growth and comparable operating margin expansion.
See More
IDEXX Laboratories to Announce Q1 Earnings on May 5
- Earnings Announcement Date: IDEXX Laboratories is set to announce its Q1 2023 earnings on May 5 before market open, with a consensus EPS estimate of $3.41, reflecting a 17.2% year-over-year increase, which could further solidify its profitability in the industry.
- Revenue Expectations: The anticipated revenue for Q1 is $1.11 billion, representing an 11.2% year-over-year growth, indicating that the company is maintaining strong sales performance amidst growing market demand, potentially attracting more investor interest.
- Historical Performance Review: Over the past two years, IDEXX has exceeded EPS estimates 100% of the time and revenue estimates 75% of the time, providing confidence to investors and showcasing the company's financial health.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates experienced 4 upward revisions and 1 downward revision, reflecting varying market perceptions of the company's future performance, which may influence investor decisions.
See More
Dover Reports Strong Q1 Results with Double-Digit Earnings Growth
- Significant Revenue Growth: Dover's Q1 revenue rose 10% year-over-year to $2.05 billion, exceeding the LSEG consensus of $2 billion, indicating strong market performance and robust customer demand.
- Surge in Orders: The company reported a 24% year-over-year increase in orders to $2.5 billion, signaling strong market demand and effective order fulfillment capabilities, which further boosts investor confidence in Dover's future performance.
- Improved Profitability: Adjusted earnings per share (EPS) reached $2.28, beating expectations by 2 cents and reflecting an 11.2% increase from the previous year, showcasing the company's success in cost control and operational efficiency.
- Optimistic Market Outlook: Dover anticipates over $1 billion in revenue by 2026 from AI and power infrastructure applications, representing 11.5% of total revenue, highlighting the company's strategic positioning and growth potential in emerging markets.
See More
IDEXX Launches Canine Cancer Detection Panel in the UK
- Early Detection Innovation: IDEXX's newly launched cancer detection panel in the UK is specifically designed for early detection of lymphoma in at-risk dogs, providing results within 3 to 5 business days, which addresses a critical clinical need and is expected to significantly enhance diagnostic efficiency for veterinarians.
- Strong Market Demand: Data indicates that 71% of UK pet owners have expressed interest in cancer screening for their pets, reflecting robust market demand for this test and further driving IDEXX's market share growth in the veterinary field.
- Significant Technical Advantages: The panel offers 79% sensitivity and 99% specificity, enabling classification of B-cell and T-cell phenotypes while also allowing monitoring of patients during chemotherapy, thereby enhancing veterinarians' decision-making capabilities in cancer management.
- Future Expansion Plans: IDEXX plans to expand the panel's capabilities over the next three years to cover the majority of canine cancer cases, further solidifying its leadership position in proactive veterinary cancer management and intervention.
See More
IDEXX Laboratories Schedules Q1 2026 Financial Results Release
- Earnings Release Schedule: IDEXX Laboratories has scheduled the release of its Q1 2026 financial results for May 5, 2026, before market open, demonstrating the company's commitment to transparency and investor communication.
- Analyst Conference Call: The company will host an analyst conference call at 8:30 AM ET on the same day, providing an interactive opportunity for investors to gain insights into the company's performance and build confidence.
- Webcast Access: Investors can access the live webcast and Q1 2026 Earnings Snapshot through the IDEXX website, ensuring broad dissemination and availability of information, which enhances the company's transparency.
- Global Impact: As a leader in pet healthcare innovation, IDEXX is dedicated to supporting the veterinary community through its diagnostic and software products, advancing medical care and improving efficiency, thereby reinforcing its significant position in the industry.
See More
IDEXX Laboratories Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: IDEXX reported a 14% year-over-year revenue increase and an 11% organic growth in Q1 2026, with earnings per share at $3.47, reflecting the company's strong performance driven by innovation and a global customer base.
- Strong Instrument Sales: CAG instrument revenues saw a 28% organic growth, primarily due to the strong sales of 1,100 IDEXX inVue Dx analyzers, indicating the company's increasing competitiveness in the high-end diagnostic equipment market.
- International Market Expansion: The successful launch of Cancer Dx for canine lymphoma in Europe and Australia, with nearly 70% of tests run as part of a panel in North America, marks IDEXX's further penetration into global markets.
- Optimistic Future Outlook: IDEXX raised its full-year revenue guidance for 2026 to between $4.675 billion and $4.760 billion, with expected earnings per share between $14.45 and $14.90, demonstrating management's confidence in future performance.
See More
IDEXX Laboratories Q1 Earnings Beat Expectations
- Earnings Beat: IDEXX reported Q1 GAAP EPS of $3.47, exceeding expectations by $0.06, indicating sustained profitability and competitive strength in the market.
- Significant Revenue Growth: The company achieved revenue of $1.14 billion, a 14.2% year-over-year increase, surpassing market expectations by $30 million, demonstrating strong product demand, particularly in the CAG Diagnostics segment.
- 2026 Revenue Guidance Raised: IDEXX increased its 2026 revenue guidance to $4.675 billion to $4.76 billion, exceeding market consensus by $420 million, with expectations that CAG Diagnostics will drive continued growth, boosting investor confidence.
- EPS Outlook Upgraded: The company raised its 2026 EPS outlook to $14.45 to $14.90, reflecting a $0.13 increase from prior guidance midpoint, supported by optimistic expectations for revenue growth and comparable operating margin expansion.
See More
IDEXX Laboratories to Announce Q1 Earnings on May 5
- Earnings Announcement Date: IDEXX Laboratories is set to announce its Q1 2023 earnings on May 5 before market open, with a consensus EPS estimate of $3.41, reflecting a 17.2% year-over-year increase, which could further solidify its profitability in the industry.
- Revenue Expectations: The anticipated revenue for Q1 is $1.11 billion, representing an 11.2% year-over-year growth, indicating that the company is maintaining strong sales performance amidst growing market demand, potentially attracting more investor interest.
- Historical Performance Review: Over the past two years, IDEXX has exceeded EPS estimates 100% of the time and revenue estimates 75% of the time, providing confidence to investors and showcasing the company's financial health.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates experienced 4 upward revisions and 1 downward revision, reflecting varying market perceptions of the company's future performance, which may influence investor decisions.
See More
Dover Reports Strong Q1 Results with Double-Digit Earnings Growth
- Significant Revenue Growth: Dover's Q1 revenue rose 10% year-over-year to $2.05 billion, exceeding the LSEG consensus of $2 billion, indicating strong market performance and robust customer demand.
- Surge in Orders: The company reported a 24% year-over-year increase in orders to $2.5 billion, signaling strong market demand and effective order fulfillment capabilities, which further boosts investor confidence in Dover's future performance.
- Improved Profitability: Adjusted earnings per share (EPS) reached $2.28, beating expectations by 2 cents and reflecting an 11.2% increase from the previous year, showcasing the company's success in cost control and operational efficiency.
- Optimistic Market Outlook: Dover anticipates over $1 billion in revenue by 2026 from AI and power infrastructure applications, representing 11.5% of total revenue, highlighting the company's strategic positioning and growth potential in emerging markets.
See More
IDEXX Launches Canine Cancer Detection Panel in the UK
- Early Detection Innovation: IDEXX's newly launched cancer detection panel in the UK is specifically designed for early detection of lymphoma in at-risk dogs, providing results within 3 to 5 business days, which addresses a critical clinical need and is expected to significantly enhance diagnostic efficiency for veterinarians.
- Strong Market Demand: Data indicates that 71% of UK pet owners have expressed interest in cancer screening for their pets, reflecting robust market demand for this test and further driving IDEXX's market share growth in the veterinary field.
- Significant Technical Advantages: The panel offers 79% sensitivity and 99% specificity, enabling classification of B-cell and T-cell phenotypes while also allowing monitoring of patients during chemotherapy, thereby enhancing veterinarians' decision-making capabilities in cancer management.
- Future Expansion Plans: IDEXX plans to expand the panel's capabilities over the next three years to cover the majority of canine cancer cases, further solidifying its leadership position in proactive veterinary cancer management and intervention.
See More
IDEXX Laboratories Schedules Q1 2026 Financial Results Release
- Earnings Release Schedule: IDEXX Laboratories has scheduled the release of its Q1 2026 financial results for May 5, 2026, before market open, demonstrating the company's commitment to transparency and investor communication.
- Analyst Conference Call: The company will host an analyst conference call at 8:30 AM ET on the same day, providing an interactive opportunity for investors to gain insights into the company's performance and build confidence.
- Webcast Access: Investors can access the live webcast and Q1 2026 Earnings Snapshot through the IDEXX website, ensuring broad dissemination and availability of information, which enhances the company's transparency.
- Global Impact: As a leader in pet healthcare innovation, IDEXX is dedicated to supporting the veterinary community through its diagnostic and software products, advancing medical care and improving efficiency, thereby reinforcing its significant position in the industry.
See More
